Por favor, use este identificador para citar o enlazar este ítem:
http://hdl.handle.net/10637/14892
Registro completo de metadatos
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.other | UCH. Departamento de Ciencias Biomédicas | - |
dc.contributor.other | UCH. Grupo de Investigación en Farmacia y Nutrición Clínica (CLINICPHARMA) | - |
dc.creator | Catalán Latorre, Ana | - |
dc.creator | Sureda, Manuel | - |
dc.creator | Brugarolas, Antonio | - |
dc.creator | Escudero Ortiz, Vanesa | - |
dc.date.accessioned | 2024-01-16T11:40:32Z | - |
dc.date.available | 2024-01-16T11:40:32Z | - |
dc.date.issued | 2021-08-01 | - |
dc.identifier.citation | Catalán-Latorre, A., Sureda, M., Brugarolas-Masllorens, A. & Escudero-Ortiz, V. (2021). Therapeutic drug monitoring of Erlotinib in non-small cell lung carcinoma: a case study. Therapeutic Drug Monitoring, vol. 43, i. 4 (01 aug.), pp. 447–450. DOI: https://doi.org/10.1097/FTD.0000000000000894 | es_ES |
dc.identifier.issn | 0163-4356 | - |
dc.identifier.issn | 1536-3694 (Electrónico) | - |
dc.identifier.uri | http://hdl.handle.net/10637/14892 | - |
dc.description | Este recurso no está disponible en acceso abierto por política de la editorial. | - |
dc.description.abstract | We describe a clinical case of an 84-year-old man diagnosed with non-small cell lung carcinoma and epidermal growth factor receptor mutation, who was treated with erlotinib, with doses adjusted by therapeutic drug monitoring. This case involved a clearance fluctuation leading to over-therapeutic drug concentrations of erlotinib and toxicity. The intrapatient and interpatient variability of erlotinib, in addition to other factors such as age or variations in liver clearance, create situations that are challenging in clinical practice. During treatment, erlotinib serum concentrations were measured, and the dose was accordingly adjusted. The erlotinib dose required to reduce toxicity (rash grade III) and maintain effective plasma concentrations, as well as clinical and radiological responses, was 50% of the initial dose, underscoring the relevance of therapeutic drug monitoring for tyrosine kinase inhibitors in routine clinical practice. | es_ES |
dc.language.iso | en | es_ES |
dc.publisher | Wolters Kluwer | es_ES |
dc.relation.ispartof | Therapeutic Drug Monitoring, vol. 43, i. 4 (01 aug.) | - |
dc.rights | http://creativecommons.org/licenses/by-nc-nd/4.0/deed.es | - |
dc.subject | Tratamiento médico | - |
dc.subject | Medical treatment | - |
dc.subject | Medicamento | - |
dc.subject | Drugs | - |
dc.subject | Cáncer | - |
dc.subject | Cancer | - |
dc.title | Therapeutic drug monitoring of Erlotinib in non-small cell lung carcinoma: a case study | es_ES |
dc.type | Artículo | es_ES |
dc.identifier.doi | https://doi.org/10.1097/FTD.0000000000000894 | - |
dc.centro | Universidad Cardenal Herrera-CEU | - |
Aparece en las colecciones: | Dpto. Ciencias Biomédicas |
Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.